×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EDIT – editas medicine, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EDIT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/4
01:12 pm
edit
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? [Yahoo! Finance]
Neutral
Report
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? [Yahoo! Finance]
3/20
04:01 pm
edit
Editas Medicine Announces Chief Financial Officer Transition
Medium
Report
Editas Medicine Announces Chief Financial Officer Transition
3/13
07:16 am
edit
Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely [Yahoo! Finance]
Medium
Report
Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely [Yahoo! Finance]
3/5
07:06 pm
edit
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates [Yahoo! Finance]
Medium
Report
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates [Yahoo! Finance]
3/5
04:05 pm
edit
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
High
Report
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
2/24
10:05 am
edit
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March [Yahoo! Finance]
Medium
Report
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March [Yahoo! Finance]
2/24
09:00 am
edit
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
Medium
Report
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
1/14
09:58 am
edit
Editas Medicine Outlines 2025 Strategic Priorities and Milestones [Yahoo! Finance]
Low
Report
Editas Medicine Outlines 2025 Strategic Priorities and Milestones [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/8
04:29 pm
edit
Form 4 Editas Medicine, Inc. For: Apr 08 Filed by: Parison Amy
High
Report
Form 4 Editas Medicine, Inc. For: Apr 08 Filed by: Parison Amy
4/8
04:21 pm
edit
Form 3 Editas Medicine, Inc. For: Mar 28 Filed by: Parison Amy
High
Report
Form 3 Editas Medicine, Inc. For: Mar 28 Filed by: Parison Amy
4/4
04:39 pm
edit
Form PRE 14A Editas Medicine, Inc. For: Apr 04
Medium
Report
Form PRE 14A Editas Medicine, Inc. For: Apr 04
3/27
04:42 pm
edit
Form 4 Editas Medicine, Inc. For: Mar 08 Filed by: Lucera Erick
Medium
Report
Form 4 Editas Medicine, Inc. For: Mar 08 Filed by: Lucera Erick
3/27
04:38 pm
edit
Form 4 Editas Medicine, Inc. For: Mar 08 Filed by: O'Neill Gilmore Neil
Medium
Report
Form 4 Editas Medicine, Inc. For: Mar 08 Filed by: O'Neill Gilmore Neil
3/27
04:34 pm
edit
Form 4 Editas Medicine, Inc. For: Mar 08 Filed by: Burkly Linda
Medium
Report
Form 4 Editas Medicine, Inc. For: Mar 08 Filed by: Burkly Linda
3/24
06:01 am
edit
Form EFFECT Editas Medicine, Inc.
Neutral
Report
Form EFFECT Editas Medicine, Inc.
3/20
04:31 pm
edit
Form 8-K Editas Medicine, Inc. For: Mar 18
Medium
Report
Form 8-K Editas Medicine, Inc. For: Mar 18
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/7
Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
7.2%
11/12 Q3/2019 9/30/2019 EPS -0.660 ZacksConsensus -0.730 ActVsEst 0.070 - Beat 6.9%
3/5 Editas Medicine Inc (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock. 5.2%
3/4 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 5.1%
8/29 Editas Medicine to Participate in Upcoming Investor Conferences 4.5%
6/14 Form 4 Editas Medicine, Inc. For: Jun 12 Filed by: Hirsch Andrew 4.0%
10/19 Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth [Yahoo! Finance News] 3.7%
11/13 Editas Expands Its Celgene Partnership After Another Strong Quarter [The Motley Fool] 3.7%
11/28 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 3.6%
5/4 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.4%
11/12 Q3/2019 9/30/2019 EPS -0.660 ZacksConsensus -0.730 ActVsEst 0.070 - Beat 6.9%
3/5 Editas Medicine Inc (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock. 5.2%
3/4 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 5.1%
8/29 Editas Medicine to Participate in Upcoming Investor Conferences 4.5%
6/14 Form 4 Editas Medicine, Inc. For: Jun 12 Filed by: Hirsch Andrew 4.0%
10/19 Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth [Yahoo! Finance News] 3.7%
11/13 Editas Expands Its Celgene Partnership After Another Strong Quarter [The Motley Fool] 3.7%
11/28 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 3.6%
5/4 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.4%
TOP News Decliners
5/10
Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-10.9%
4/1 Better Buy: Editas Medicine vs Sangamo Therapeutics [The Motley Fool] -8.1%
2/26 Form S-8 Editas Medicine, Inc. -6.8%
2/21 Editas Medicine Inc (NASDAQ: EDIT) is now covered by analysts at Wells Fargo & Co. They set an "equal weight" rating and a $28.00 price target on the stock. -6.7%
2/22 Better Buy: Editas Medicine vs. Intellia [The Motley Fool] -6.2%
7/30 Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update -5.8%
8/27 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.1%
4/30 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update -4.9%
11/26 Better Buy: Editas Medicine or Sangamo Therapeutics? [The Motley Fool] -4.6%
3/20 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.6%
4/1 Better Buy: Editas Medicine vs Sangamo Therapeutics [The Motley Fool] -8.1%
2/26 Form S-8 Editas Medicine, Inc. -6.8%
2/21 Editas Medicine Inc (NASDAQ: EDIT) is now covered by analysts at Wells Fargo & Co. They set an "equal weight" rating and a $28.00 price target on the stock. -6.7%
2/22 Better Buy: Editas Medicine vs. Intellia [The Motley Fool] -6.2%
7/30 Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update -5.8%
8/27 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.1%
4/30 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update -4.9%
11/26 Better Buy: Editas Medicine or Sangamo Therapeutics? [The Motley Fool] -4.6%
3/20 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: